PEN as reported
Penumbra, Inc. reported $1.45B of revenue over the trailing twelve months, +17% on the year before. 10 reported series are charted on this page, each one as filed.
$1.45B
Revenue, trailing twelve months · to Q1 2026 · +17% against the twelve months before
- Net Income
- $171M
Net Income · +305% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $213M
Free Cash Flow · +42% year on year · trailing twelve months to Q1 2026
- Op Margin
- 13%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $1.45B | +17% | Q1 2026 |
| Net Income | $171M | +305% | Q1 2026 |
| EPS | $4.34 | +306% | Q1 2026 |
| Gross Margin | 67% | n/a | Q1 2026 |
| Op Margin | 13% | n/a | Q1 2026 |
| Net Margin | 12% | n/a | Q1 2026 |
| ROE | 12% | n/a | Q1 2026 |
| ROA | 9.2% | n/a | Q1 2026 |
| Free Cash Flow | $213M | +42% | Q1 2026 |
| P/E | 74.5 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Penumbra, Inc. (PEN) - Revenue & ProfitRevenue & ProfitPenumbra, Inc. (PEN)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Medical Devices
Ranks #19 of 35 by Smart Score